

DO NOT  
enter  
CCH  
3-18-05

IN THE CLAIMS

Please amend claims 116 and 164, as shown below. Please cancel claims 132-137, 142-145, 152-159, 161-163, 167, and 175-177 without prejudice. The following listing of claims replaces all prior listings.

1-115. (Canceled).

116. (Currently amended) A method for enhancing the delivery of a bioactive agent from the vasculature to a selected tissue in a patient, comprising:

(i) administering said bioactive agent to said patient;

(ii) administering a vesicle composition to said patient, by intravascular infusion, wherein said vesicle composition comprises, in an aqueous carrier, vesicles comprising lipids, proteins, or polymers and a gas or gaseous precursor; and

(iii) cavitating and/or rupturing said vesicles by applying to the patient ultrasonic energy having a frequency between about 750 kHz and 3 MHz, to the patient in an amount sufficient to produce cavitation or rupture of said vesicles, and sufficient to increase thereby enhance delivery of said bioactive agent from the vasculature through the vessel wall and into said selected tissue, wherein said bioactive agent is delivered into said selected tissue, wherein said ultrasound energy has a frequency between about 750 kHz and 3 MHz.

117. (Previously presented) A method according to Claim 116 wherein said bioactive agent is administered to said patient at a rate which comprises continuous infusion.

118. (Previously presented) A method according to Claim 116 wherein said bioactive agent and said vesicle composition are administered to said patient substantially simultaneously.